

Nepal support for Measles vaccine

This decision letter sets out the Programme Terms of a Programme.

1. Country: Nepal			
2. Grant number: 1516-NPL-09a-X			
3. Date of decision letter: 19 November 2015			
4. Date of the Partnership Framework Agreement: 22 August 2014			
5. Programme title: New vaccine support (NVS), Measles second dose, Routine			
6. Vaccine type: Measles-Rubella			
7. Requested product presentation and formulation of vaccine: Measles-Rubella, 10 doses per vial, LYOPHILISED			
8. Programme duration¹: 2015 - 2016			
9. Programme budget (indicative): (subject to the terms of the Partnership Framework Agreement)			
	2015	2016	Total ²
Programme budget (US\$)	US\$348,500 ³	US\$391,000	US\$739,500
10. Vaccine introduction grant (in US\$): Not applicable			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁴			
Type of supplies to be purchased with Gavi funds in each year	2015	2016	
Number of Measles vaccines doses		988,200	
Number of AD syringes		684,600	
Number of re-constitution syringes		108,700	
Number of safety boxes		8,750	
Annual Amounts (US\$)	US\$348,500 ⁵	US\$391,000	
12. Procurement agency: UNICEF			
13. Self-procurement: Not applicable			
14. Co-financing obligations: Not applicable			
15. Operational support for campaigns: Not applicable			

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved. The Annual Amount for 2016 has been amended.

⁵ This is the consolidated amount for all previously approved years.

16. Additional reporting requirements: Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due date
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

17. Financial clarifications: Not applicable

18. Other conditions:

Country has presented an official request to Gavi to switch from measles vaccine to Measles-Rubella vaccine for the routine measles second dose with Country funding for the equivalent cost of the rubella component. As such, Country will make the required payments to UNICEF SD as indicated in the table below:

	2016
Number of doses of vaccines for Measles Second Dose approved by Gavi	988,200
Amount for vaccines approved by Gavi in US\$ (excluding freight and insurance)	US\$316,224
Number of doses of Measles-Rubella vaccine that can be purchased with Gavi support	518,400
Number of doses of Measles-Rubella vaccine to be funded by Country	469,800
Amount for Measles-Rubella vaccines to be funded by Country in US\$ (excluding freight and insurance)	US\$286,578

Country understands that vaccines will be purchased only after receipt of full payment of the respective amounts due from Country and Gavi by the procurement agency for the number of doses as indicated in this Decision Letter. In the event that Country wishes to revert to measles vaccine, Country should inform UNICEF and Gavi Secretariat immediately in order to agree on an appropriate arrangement.

Country is also reminded of its obligations under the Partnership Framework Agreement in respect of insurance and is requested to provide information to Gavi Secretariat on the steps it has taken in this regard.

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
19 November 2015

Nepal support for Pneumococcal vaccine

This decision letter sets out the Programme Terms of a Programme.

1. Country: Nepal			
2. Grant number: 1416-NPL-12b-X			
3. Date of decision letter: 19 November 2015			
4. Date of the Partnership Framework Agreement: 22 August 2014			
5. Programme title: New vaccine support (NVS), Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV10), 2 dose(s) per vial, LIQUID			
8. Programme duration¹: 2014 - 2016 ²			
9. Programme budget (indicative): (subject to the terms of the Partnership Framework Agreement)			
	2014 - 2015	2016	Total ³
Programme budget (US\$)	US\$10,548,500 ⁴	US\$6,400,000	US\$16,948,500
10. Vaccine introduction grant (in US\$): Not applicable			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁵			
Type of supplies to be purchased with Gavi funds in each year	2014 - 2015	2016	
Number of Pneumococcal vaccines doses		1,324,000	
Number of AD syringes		1,331,000	
Number of re-constitution syringes		-	
Number of safety boxes		14,650	
Annual Amounts (US\$)	US\$10,548,500 ⁶	US\$6,400,000	
12. Procurement agency: UNICEF Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable			

¹ This is the entire duration of the Programme.

² Programme did not begin until 2015 due to delay in introduction.

³ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁴ This is the consolidated amount for all previous years.

⁵ This is the amount that Gavi has approved. The Annual Amounts for 2014 to 2016 have been amended.

⁶ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: Reference code: 1416-NPL-12b-X-C

According to the co-financing policy, Country falls within the group Initial self-financing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2016
Number of vaccine doses	82,800
Number of AD syringes	-
Number of re-constitution syringes	-
Number of safety boxes	-
Value of vaccine doses (US\$)	US\$278,851
Total co-financing payments (US\$) (including freight)	US\$281,500

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements: Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

Country is reminded of its obligations under the Partnership Framework Agreement in respect of insurance and is requested to provide information to Gavi Secretariat on the steps it has taken in this regard.

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
19 November 2015

Nepal support for Pentavalent vaccine

This decision letter sets out the Programme Terms of a Programme.

1. Country: Nepal			
2. Grant number: 16-NPL-04c-X			
3. Date of decision letter: 19 November 2015			
4. Date of the Partnership Framework Agreement: 22 August 2014			
5. Programme title: New vaccine support (NVS), Pentavalent, Routine			
6. Vaccine type: Pentavalent			
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID			
8. Programme duration¹: 2009 - 2016			
9. Programme budget (indicative): (subject to the terms of the Partnership Framework Agreement)			
	2009 - 2015	2016	Total ²
Programme budget (US\$)	US\$33,858,890 ³	US\$2,896,500	US\$36,755,390
10. Vaccine introduction grant (in US\$): Not applicable			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁴			
Type of supplies to be purchased with Gavi funds in each year	2009 - 2015	2016	
Number of Pentavalent vaccines doses		1,538,000	
Number of AD syringes		1,406,800	
Number of re-constitution syringes		-	
Number of safety boxes		15,475	
Annual Amounts (US\$)	US\$33,858,890 ⁵	US\$2,896,500	
12. Procurement agency: UNICEF Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable			

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: Reference code: 16-NPL-04c-X-C

According to the co-financing policy, Country falls within the group Initial self-financing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2016
Number of vaccine doses	188,000
Number of AD syringes	-
Number of re-constitution syringes	-
Number of safety boxes	-
Value of vaccine doses (US\$)	US\$337,770
Total co-financing payments (US\$) (including freight)	US\$345,500

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements: Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.


Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

Country is reminded of its obligations under the Partnership Framework Agreement in respect of insurance and is requested to inform the Gavi Secretariat on the steps it has taken in this regard.

Signed by,



On behalf of Gavi
 Hind Khatib-Othman
 Managing Director, Country Programmes
 19 November 2015